Smoking cessation for secondary prevention of cardiovascular disease

Wu, Angela Difeng; Lindson, Nicola; Hartmann‐Boyce, Jamie; Wahedi, Azizia; Hajizadeh, Anisa; Theodoulou, Annika; Thomas, Elizabeth T; Lee, Charlotte; Aveyard, Paul

doi:10.1002/14651858.cd014936.pub2

Cited by 27 publications

(14 citation statements)

References 116 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a meta-analysis of 18 studies and 17 982 adult participants with CHD who were smoking at the time of diagnosis, smoking cessation was associated with a lower risk of cardiovascular death (HR, 0.61 [95% CI, 0.49–0.75]). 71 A secondary analysis including 9 studies and 11 352 participants showed that smoking cessation was associated with a lower risk of nonfatal stroke (HR, 0.70 [95% CI, 0.53–0.90]).…”

Section: Stroke (Cerebrovascular Diseases)mentioning

confidence: 99%

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Martin,

Aday,

Almarzooq

et al. 2024

Circulation

216

View full text Add to dashboard Cite

BACKGROUND: The American Heart Association (AHA), in conjunction with the National Institutes of Health, annually reports the most up-to-date statistics related to heart disease, stroke, and cardiovascular risk factors, including core health behaviors (smoking, physical activity, nutrition, sleep, and obesity) and health factors (cholesterol, blood pressure, glucose control, and metabolic syndrome) that contribute to cardiovascular health. The AHA Heart Disease and Stroke Statistical Update presents the latest data on a range of major clinical heart and circulatory disease conditions (including stroke, brain health, complications of pregnancy, kidney disease, congenital heart disease, rhythm disorders, sudden cardiac arrest, subclinical atherosclerosis, coronary heart disease, cardiomyopathy, heart failure, valvular disease, venous thromboembolism, and peripheral artery disease) and the associated outcomes (including quality of care, procedures, and economic costs). METHODS: The AHA, through its Epidemiology and Prevention Statistics Committee, continuously monitors and evaluates sources of data on heart disease and stroke in the United States and globally to provide the most current information available in the annual Statistical Update with review of published literature through the year before writing. The 2024 AHA Statistical Update is the product of a full year’s worth of effort in 2023 by dedicated volunteer clinicians and scientists, committed government professionals, and AHA staff members. The AHA strives to further understand and help heal health problems inflicted by structural racism, a public health crisis that can significantly damage physical and mental health and perpetuate disparities in access to health care, education, income, housing, and several other factors vital to healthy lives. This year’s edition includes additional global data, as well as data on the monitoring and benefits of cardiovascular health in the population, with an enhanced focus on health equity across several key domains. RESULTS: Each of the chapters in the Statistical Update focuses on a different topic related to heart disease and stroke statistics. CONCLUSIONS: The Statistical Update represents a critical resource for the lay public, policymakers, media professionals, clinicians, health care administrators, researchers, health advocates, and others seeking the best available data on these factors and conditions.

show abstract

Section: Stroke (Cerebrovascular Diseases)mentioning

confidence: 99%

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Martin,

Aday,

Almarzooq

et al. 2024

Circulation

216

View full text Add to dashboard Cite

show abstract

“…Additionally, smoking is known to increase total serum cholesterol, VLDL, LDL, and triglyceride serum concentrations, which in turn increases the risk of atherosclerosis and other forms of CVDs [50]. The cessation of smoking was found to significantly reduce the risk of CVD events such as nonfatal myocardial infarctions, nonfatal strokes, and death [51]. The repercussions of smoking also do not just end at the individual level.…”

Section: Smokingmentioning

confidence: 99%

Traditional Therapeutics and Potential Epidrugs for CVD: Why Not Both?

Gladwell,

Ahiarah,

Rasheed

et al. 2023

Life

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the leading cause of death worldwide. In addition to the high mortality rate, people suffering from CVD often endure difficulties with physical activities and productivity that significantly affect their quality of life. The high prevalence of debilitating risk factors such as obesity, type 2 diabetes mellitus, smoking, hypertension, and hyperlipidemia only predicts a bleak future. Current traditional CVD interventions offer temporary respite; however, they compound the severe economic strain of health-related expenditures. Furthermore, these therapeutics can be prescribed indefinitely. Recent advances in the field of epigenetics have generated new treatment options by confronting CVD at an epigenetic level. This involves modulating gene expression by altering the organization of our genome rather than altering the DNA sequence itself. Epigenetic changes are heritable, reversible, and influenced by environmental factors such as medications. As CVD is physiologically and pathologically diverse in nature, epigenetic interventions can offer a ray of hope to replace or be combined with traditional therapeutics to provide the prospect of addressing more than just the symptoms of CVD. This review discusses various risk factors contributing to CVD, perspectives of current traditional medications in practice, and a focus on potential epigenetic therapeutics to be used as alternatives.

show abstract

“…Bei Patienten mit Lungen-, kardiovaskulären-und Krebserkrankungen sowie einer Vielzahl weiterer chronischer Erkrankungen führt der Rauchstopp zu einer Verbesserung der Symptomatik und Prognose [5]. Dies konnte beispielhaft das Cochrane-Review zur Tabakentwöhnung und koronaren Herzerkrankung zeigen, wo der Rauchstopp das Risiko für die KHK um ein Drittel senkt [29].…”

Section: Grundlagen Der Tabakentwöhnungunclassified

Die E-Zigarette – Mittel zur Tabakentwöhnung?

Franzen¹,

Pankow²,

Andreas³

2022

Dtsch Med Wochenschr

View full text Add to dashboard Cite

Was ist neu? Tabakentwöhnung in Deutschland. Nachdem der Tabakkonsum über mehrere Jahre rückläufig war, zeigt sich aktuell eine Stagnation bzw. ein Wiederanstieg der Rauchenden in Deutschland. Die Ursachen erscheinen vielfältig, wie z. B. Belastungen durch die Pandemie mit der sozialen Isolation, steigende Lebenshaltungskosten und Krieg in Europa. Bei einem weiterhin stark verbreiteten Tabakkonsum in der deutschen Bevölkerung wird eine evidenzbasierte Tabakentwöhnung nur selten durchgeführt. Gesundheitsrisiken der E-Zigarette. Nach neueren Studien sind E-Zigaretten an der Pathogenese von Lungenerkrankungen, Herz- und Gefäßschädigungen beteiligt. Zudem wirken ihre Inhaltsstoffe auch karzinogen. Klinische Untersuchungen zum dauerhaften Konsum liegen aber bisher nicht vor. Wie wirksam ist die E-Zigarette bei der Tabakentwöhnung? E-Zigaretten als Konsumentenprodukt sind den in Leitlinien empfohlenen Nikotin-Ersatzpräparaten und suchthemmenden Medikamenten nicht überlegen. Im therapeutischen Setting sind sie etwas besser wirksam als Nikotin-Ersatzpräparate. Sie werden aber meistens dauerhaft konsumiert und verstetigen so die Nikotinabhängigkeit. Ihr Konsum erhöht die Rückfallgefahr zum Tabakrauchen. Evidenzbasierte Tabakentwöhnung ambulant und stationär. Trotz der verschiedenen neuen Ansätze, wie Internet-basierte Angebote, App etc., sind Gespräche und Pharmakotherapie der Goldstandard und wirksamer als jede Therapie für sich allein.

show abstract

Smoking cessation for secondary prevention of cardiovascular disease

Cited by 27 publications

References 116 publications

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association

Traditional Therapeutics and Potential Epidrugs for CVD: Why Not Both?

Die E-Zigarette – Mittel zur Tabakentwöhnung?

Contact Info

Product

Resources

About